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A commentary on
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epithelial tumours: a multicentre, open-
label, phase 2 trial
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S1470-2045(13)70596-5
Thymic epithelial tumors (TETs) are
comprised of a spectrum of histolog-
ically distinct tumors that also exhibit
differences at the molecular level (1).
Surgery is the mainstay of treatment but
locally advanced and metastatic TETs can
be inoperable and are associated with
worse survival (2). Although multi-agent
chemotherapy is associated with objec-
tive response rates (ORR) of 50–90% in
the front-line setting [e.g., cisplatin, dox-
orubicin, and cyclophosphamide (CAP)
(3), doxorubicin, cisplatin, vincristine, and
cyclophosphamide (ADOC) (4)], no stan-
dard systemic treatments exist for relapsed
or refractory TETs. Several biological
agents have been evaluated in TETs in
small phase II trials as illustrated in
Table 1.
SOMATOSTATIN ANALOGS
Somatostatin receptors are expressed in
TETs and can be detected by octreotide
scan (17). Palmieri et al. first showed effi-
cacy of octreotide/lanreotide with or with-
out prednisone in TETs (5). In another
larger phase II trial, 38 patients with
octreotide scan-positive TETs were treated
with octreotide for 2 months. Respond-
ing patients continued to receive octreotide
alone whereas patients with stable dis-
ease received additional prednisone for a
maximum of 10 additional months. Two
complete (5.3%) and 10 partial responses
(25%) were observed in patients with
thymoma, but no response was seen in
thymic carcinoma (6).
HISTONE DEACETYLASE INHIBITORS
Histone deacetylases (HDACs) regulate
gene expression through chromosome
remodeling. Belinostat is a HDAC inhibitor
that has been evaluated in a phase II
trial in patients with advanced TETs after
failure of platinum-containing chemother-
apy (7). Among 25 patients with thy-
moma, and 16 with thymic carcinoma, two
patients with thymoma achieved partial
responses. No responses were seen among
patients with thymic carcinoma. Median
time to progression in patients with thy-
moma and thymic carcinoma was 11.4 and
2.7 months, respectively. Median survival
was not reached in patients with thymoma
and it was 12.4 months in patients with
thymic carcinoma. Belinostat has also been
evaluated with CAP in the front-line setting
in a phase I/II trial. The overall response
rate was 71% in thymoma and 33% in
thymic carcinoma (8).
INSULIN-LIKE GROWTH FACTOR
RECEPTOR INHIBITORS
Thymic epithelial tumors express insulin-
like growth factor-1 receptor (IGF-1R),
particularly recurrent or advanced tumors
and those with aggressive histological
subtypes (18). Cixutumumab, a fully
human IgG1 monoclonal antibody that
binds to IGF-1R with high affinity and
induces internalization and degradation
of the receptor, has been evaluated in a
phase II trial of 37 patients with thy-
moma and 12 patients with thymic carci-
noma, who had progressive disease after
prior platinum-containing chemotherapy
(9). Patients received cixutumumab at
a dose of 20 mg/kg intravenously every
3 weeks until disease progression or devel-
opment of intolerable toxicities. With a
median follow up of 24 months, 5 of
37 thymoma patients achieved a par-
tial response (ORR 14%). The median
time to progression was 9.9 months and
median survival was 27.5 months. In con-
trast, no responses were seen in patients
with thymic carcinoma and the median
time to progression and overall survival
were 1.7 and 8.4 months, respectively. A
significant increase in IFNγ-expressing
CD4+ T cells and reduction in circu-
lating endothelial progenitor cells (CEPs)
were observed with treatment among
responders. The potential predictive value
of these biomarkers is under further
investigation.
MULTIKINASE INHIBITORS
Multiple case reports have described
responses to the multikinase inhibitors,
sorafenib (19) and sunitinib (20) in
patients with previously treated thymic car-
cinoma. To confirm the activity of suni-
tinib in previously treated TETs, 22 patients
with thymoma and 16 with thymic carci-
noma with progressive disease following
at least one platinum-based chemother-
apy regimen were enrolled in a phase II
study. Sunitinib was administered orally
at a dose of 50 mg once daily in 6-week
cycles (4 weeks on 2 weeks off). In 19 evalu-
able patients with thymic carcinoma and 16
evaluable patients with thymoma, the ORR
was 16 and 6%, respectively, and PFS was
6.2 and 5.5 months, respectively. Adverse
events included cytopenia, fatigue, mucosi-
tis, hypertension, and reversible decline
in left ventricular ejection. Additionally,
10 (53%) patients with thymic carcinoma
had tumor shrinkage between 10 and
29% (12).
EPIDERMAL GROWTH FACTOR
RECEPTOR, KIT AND Src INHIBITORS
Despites preclinical data demonstrating
overexpression of epidermal growth factor
receptor (EGFR) (21) and KIT (22) and
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Table 1 | Published biological therapies inTETs.
Trial Agent Target N ORR (%)
(CR+PR)
TTP
(months)
PFS
(months)
Survival
(months)
Palmieri et al. (5) Octreotide/lanreotide±prednisone Somatostatin receptor 16 6 (37) 14 NR 15
Thymoma 10 4 (40) NR NR NR
Thymic carcinoma 3 1 (33) NR NR NR
Loehrer et al. (6) Octreotide±prednisone Somatostatin receptor 38 12 (32) NR NR NR
Thymoma 32 12 (38) 8.8 NR Not reached
Thymic carcinoma 6 0 4.5 NR 23.4
Giaccone et al. (7) Belinostat HDAC 40 2 (5) NR NR NR
Thymoma 24 2 (8) 11.4 NR Not reached
Thymic carcinoma 16 0 2.7 NR 12.4
Thomas et al. (8) PAC–belinostat HDAC 13 7 (54) NR NR NR
Thymoma 7 5 (71) NR NR NR
Thymic carcinoma 6 2 (33) NR NR NR
Rajan et al. (9) Cixutumumab IGF-1R 49 5 (10) NR NR NR
Thymoma 37 5 (14) 9.9 NR 27.5
Thymic carcinoma 12 0 1.7 NR 8.4
Kurup et al. (10) Gefitinib EGFR 26 1 (4) 4 NR NR
Thymoma 19 NR NR NR NR
Thymic carcinoma 7 NR NR NR NR
Bedano et al. (11) Erlotinib+bevacizumab EGFR 18 0 NR NR NR
Thymoma VEGF 11 0 NR NR Not reached
Thymic carcinoma 7 0 NR NR Not reached
Thomas et al. (12) Sunitinib VEGFR 35 4 (11) NR NR NR
Thymoma PDGFR 16 1 (6) NR 5.5 NR
Thymic carcinoma 19 3 (16) NR 6.2 NR
Salter et al. (13) Imatinib KIT 11 0 NR NR NR
Thymoma PDGFR 0
Thymic carcinoma 11 0 NR NR NR
Giaccone et al. (14) Imatinib KIT 7 0 2 NR 4
Thymoma PDGFR 2 0 8.5 NR Not reached
Thymic carcinoma 5 0 1 NR 2
Palmieri et al. (15) Imatinib KIT 15 0 NR 3 Not reached
Thymoma PDGFR 12 0 NR NR NR
Thymic carcinoma 3 0 NR NR NR
Wakelee et al. (16) Saracatinib SRC 21 0 NR NR NR
Thymoma 14 NR NR 3.4 Not reached
Thymic carcinoma 7 NR NR 1.4 Not reached
NR, not reported.
Src Kinase (23) in TETs, very low objec-
tive responses were observed in phase II
studies evaluating these agents. A study
using EGFR inhibitor, Gefitinib, yields only
one response in 26 patients (10) while
another study using Erlotinib plus Beva-
cizumab showed no response (11). Three
trials evaluating KIT inhibitor Imatinib
in TETs (13–15) showed zero objective
response. It is notable that although most
tumors on these trials overexpressed KIT,
no sensitizing mutation was found. Src
inhibitor Saracatinib also failed to yield
any objective response in a TET trial (16).
For more details on these studies, see
Table 1.
ONGOING TRIALS OF TARGETED
THERAPIES IN TETs
Milciclib, an inhibitor of cyclin-
dependent kinase 2/cyclin A com-
plex and tropomyosin receptor kinase
A (TrkA) is being evaluated in two
phase II studies in patients with
recurrent B3 thymoma and thymic
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carcinoma (NCT01011439 and NCT
01301391).
A phase II study is evaluating the role
of the mammalian target of rapamycin
(mTOR) inhibitor, everolimus in patients
with TETs previously treated with
chemotherapy. (NCT02049047).
CONCLUSION
In conclusion, although the presence of
targetable mutations detected by current
techniques of molecular profiling is low,
whole genome and exome sequencing has
the potential to uncover novel biological
targets. Although many trials of targeted
agents have yielded disappointing results,
the unprecedented activity of sunitinib in
thymic carcinoma and the disease stabi-
lizing effect of cixutumumab in thymoma
provides an impetus to continue to explore
the role of novel biological agents in TETs.
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